SphK Inhibitor

SphK Inhibitors (20):

Cat. No.	Product Name	Effect	Purity

HY-13822

SKI II	Inhibitor	99.78%
SKI-II is an oral active and synthetic inhibitor of sphingosine kinase (SK) activity, with IC₅₀ values of 78 μM and 45 μM for SK1 and for SK2, respectively. SKI II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation.

HY-16015

Opaganib	Inhibitor	99.94%
Opaganib (ABC294640) is a selective, competitive sphingosine kinase 2 (SK2) inhibitor with K_i of 9.8 μM.

HY-100008

Peretinoin	Inhibitor	99.79%
Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as retinoid X receptor (RXR) and retinoic acid receptor (RAR). Peretinoin reduces the mRNA level of sphingosine kinase 1 (SPHK1) in vitro by downregulating a transcription factor, Sp1. Peretinoin prevents the progression of non-alcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) through activating the autophagy pathway by increased Atg16L1 expression. Peretinoin inhibits HCV RNA amplification and virus release by altering lipid metabolism with a EC₅₀ of 9 μM.

HY-108491

N,N-Dimethylsphingosine	Inhibitor	99.4%
N,N-Dimethylsphingosine is a potent inhbitor of SphK (sphingosine kinase) as an endogenous metabolite of sphingosine produced in various tissues and tumor cell lines.

HY-115735

SKI-I	Inhibitor	99.14%
SKI-I is a potent and selective inhibitor of human sphingosine kinase (SK), with an IC₅₀ of 1.2 μM for ST-hSK. SKI-I also inhibits hERK2 (IC₅₀=11 μM). SKI-I induces apoptosis in tumor cell lines.

HY-100008R

Peretinoin (Standard)	Inhibitor
Peretinoin (Standard) is the analytical standard of Peretinoin. This product is intended for research and analytical applications. Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as retinoid X receptor (RXR) and retinoic acid receptor (RAR). Peretinoin reduces the mRNA level of sphingosine kinase 1 (SPHK1) in vitro by downregulating a transcription factor, Sp1[1]. Peretinoin prevents the progression of non-alcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) through activating the autophagy pathway by increased Atg16L1 expression[2]. Peretinoin inhibits HCV RNA amplification and virus release by altering lipid metabolism with a EC50 of 9 μM[3].

HY-120268

SLM6031434	Inhibitor
SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with K_is of 0.4 μM, 0.5 μM, >20 μM, 22 μM for mSphK2, rSphK2, mSphK1 and rSphK1, respectively. SLM6031434 decrease Sphingosine 1-phosphate (S1P) levels in U937 monocytic leukemia cells. SLM6031434 has the potential for renal fibrosis research.

HY-120268A

SLM6031434 hydrochloride	Inhibitor	99.1%
SLM6031434 hydrochloride is a highly selective sphingosine kinase 2 (SphK2) inhibitor with K_is of 0.4 μM, 0.5 μM, >20 μM, 22 μM for mSphK2, rSphK2, mSphK1 and rSphK1, respectively. SLM6031434 hydrochloride decrease Sphingosine 1-phosphate (S1P) levels in U937 monocytic leukemia cells. SLM6031434 hydrochloride has the potential for renal fibrosis research.

HY-150513

SLP9101555	Inhibitor	99.40%
SLP9101555 (compound 14c) is a potent and selective SphK2 (sphingosine kinase 2) inhibitor (K_i=90 nM) with 200-fold selectivity over SphK1. SLP9101555 markedly decreases extracellular S1P (sphingosine 1-phosphate) levels.

HY-12895

SKI V	Inhibitor	98.95%
SKI V is a noncompetitive and potent non-lipid sphingosine kinase (SPHK; SK) inhibitor with an IC₅₀ of 2 μM for GST-hSK. SKI V potently inhibits PI3K with an IC₅₀ of 6 μM for hPI3k. SKI V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P). SKI V induces apoptosis and has antitumor activity.

HY-162143

SKI-349	Inhibitor	99.58%
SKI-349 is a dual-targeted inhibitor of sphingosine kinase 1/2 (SPHK1/2) and microtubule assembly (MDA). SKI-349 has anticancer activity. SKI-349 can inhibit the vitality, invasion, and AKT/mTOR signaling pathway of liver cells.

HY-15779

K145	Inhibitor
K145 is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC₅₀ of 4.3 µM and a K_i of 6.4 µM. K145 is inactive against SphK1 and other protein kinases. K145 induces cell apoptosis and has potently antitumor activity.

HY-RS13667

SPHK2 Human Pre-designed siRNA Set A	Inhibitor
SPHK2 Human Pre-designed siRNA Set A contains three designed siRNAs for SPHK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS13666

Sphk1 Rat Pre-designed siRNA Set A	Inhibitor
Sphk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sphk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS13664

SPHK1 Human Pre-designed siRNA Set A	Inhibitor
SPHK1 Human Pre-designed siRNA Set A contains three designed siRNAs for SPHK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS13668

Sphk2 Mouse Pre-designed siRNA Set A	Inhibitor
Sphk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sphk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-151351

SphK2-IN-2	Inhibitor
SphK2-IN-2 (21g) is a potent and selective SphK2 inhibitor with an IC₅₀ value of 0.23 μM.

HY-RS13665

Sphk1 Mouse Pre-designed siRNA Set A	Inhibitor
Sphk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sphk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-162580

SphK2-IN-3	Inhibitor
SphK2-IN-3 (compound 12q) is a selective active sphingosine kinase-2 inhibitor. SphK2-IN-3 has anti-proliferative activity against various cancer cells, inducing G2 phase arrest and apoptosis in liver cancer cells HepG2.

HY-16015A

Opaganib hydrochloride	Inhibitor
Opaganib (ABC294640) hydrochloride is a selective, competitive sphingosine kinase 2 (SK2) inhibitor with K_i of 9.8 μM.

Name
Email *

	Sorry, but the email address you supplied was invalid.